vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Vivid Seats Inc. (SEAT). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $97.5M, roughly 1.9× Vivid Seats Inc.). Vivid Seats Inc. runs the higher net margin — 1212.8% vs 13.3%, a 1199.4% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -41.0%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-38.3M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -21.9%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Vivid Seats Inc. is an American online ticket market place and resale company. It is the official ticketing partner of numerous sports teams and media outlets including ESPN, United Airlines, the San Francisco 49ers and the Los Angeles Chargers. Its rewards program allows fans to earn points on purchases. Vivid Seats is a member of the Internet Association, which advocates for net neutrality.
AMPH vs SEAT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $97.5M |
| Net Profit | $24.4M | $1.2B |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | 1212.8% |
| Revenue YoY | -1.8% | -41.0% |
| Net Profit YoY | -35.7% | 12369.2% |
| EPS (diluted) | $0.51 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $97.5M | ||
| Q3 25 | $191.8M | $104.8M | ||
| Q2 25 | $174.4M | $114.5M | ||
| Q1 25 | $170.5M | $133.7M | ||
| Q4 24 | $186.5M | $165.2M | ||
| Q3 24 | $191.2M | $152.7M | ||
| Q2 24 | $182.4M | $170.0M | ||
| Q1 24 | $171.8M | $160.0M |
| Q4 25 | $24.4M | $1.2B | ||
| Q3 25 | $17.4M | $-30.2M | ||
| Q2 25 | $31.0M | $-335.4M | ||
| Q1 25 | $25.3M | $-10.6M | ||
| Q4 24 | $38.0M | $-9.6M | ||
| Q3 24 | $40.4M | $10.6M | ||
| Q2 24 | $37.9M | $-437.0K | ||
| Q1 24 | $43.2M | $12.9M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | — | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | 27.9% | — |
| Q4 25 | 13.3% | 1212.8% | ||
| Q3 25 | 9.0% | -28.9% | ||
| Q2 25 | 17.8% | -293.0% | ||
| Q1 25 | 14.8% | -7.9% | ||
| Q4 24 | 20.4% | -5.8% | ||
| Q3 24 | 21.1% | 7.0% | ||
| Q2 24 | 20.8% | -0.3% | ||
| Q1 24 | 25.1% | 8.0% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $102.7M |
| Total DebtLower is stronger | $608.7M | $16.5M |
| Stockholders' EquityBook value | $788.8M | $-85.1M |
| Total Assets | $1.6B | $636.9M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $102.7M | ||
| Q3 25 | $276.2M | $145.1M | ||
| Q2 25 | $231.8M | $153.0M | ||
| Q1 25 | $236.9M | $199.5M | ||
| Q4 24 | $221.6M | $243.5M | ||
| Q3 24 | $250.5M | $202.3M | ||
| Q2 24 | $217.8M | $234.3M | ||
| Q1 24 | $289.6M | $154.0M |
| Q4 25 | $608.7M | $16.5M | ||
| Q3 25 | $608.6M | $17.1M | ||
| Q2 25 | $607.7M | $17.7M | ||
| Q1 25 | $603.9M | $18.2M | ||
| Q4 24 | $601.6M | $18.7M | ||
| Q3 24 | $596.4M | $15.8M | ||
| Q2 24 | $586.9M | $16.1M | ||
| Q1 24 | $594.0M | $15.7M |
| Q4 25 | $788.8M | $-85.1M | ||
| Q3 25 | $776.7M | $272.2M | ||
| Q2 25 | $757.5M | $217.3M | ||
| Q1 25 | $751.3M | $380.7M | ||
| Q4 24 | $732.3M | $261.1M | ||
| Q3 24 | $727.7M | $329.4M | ||
| Q2 24 | $713.3M | $155.8M | ||
| Q1 24 | $672.4M | $139.6M |
| Q4 25 | $1.6B | $636.9M | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.6B | $1.1B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.7B | ||
| Q1 24 | $1.6B | $1.6B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | 0.06× | ||
| Q2 25 | 0.80× | 0.08× | ||
| Q1 25 | 0.80× | 0.05× | ||
| Q4 24 | 0.82× | 0.07× | ||
| Q3 24 | 0.82× | 0.05× | ||
| Q2 24 | 0.82× | 0.10× | ||
| Q1 24 | 0.88× | 0.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-38.2M |
| Free Cash FlowOCF − Capex | $24.6M | $-38.3M |
| FCF MarginFCF / Revenue | 13.4% | -39.3% |
| Capex IntensityCapex / Revenue | 4.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.35× | -0.03× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-93.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-38.2M | ||
| Q3 25 | $52.6M | $512.0K | ||
| Q2 25 | $35.6M | $-28.6M | ||
| Q1 25 | $35.1M | $-25.3M | ||
| Q4 24 | $29.0M | $47.8M | ||
| Q3 24 | $60.0M | $-19.2M | ||
| Q2 24 | $69.1M | $-13.8M | ||
| Q1 24 | $55.3M | $39.2M |
| Q4 25 | $24.6M | $-38.3M | ||
| Q3 25 | $47.2M | $502.0K | ||
| Q2 25 | $25.0M | $-28.8M | ||
| Q1 25 | $24.4M | $-27.1M | ||
| Q4 24 | $16.6M | $44.3M | ||
| Q3 24 | $46.2M | $-19.6M | ||
| Q2 24 | $63.1M | $-14.1M | ||
| Q1 24 | $46.5M | $39.1M |
| Q4 25 | 13.4% | -39.3% | ||
| Q3 25 | 24.6% | 0.5% | ||
| Q2 25 | 14.3% | -25.2% | ||
| Q1 25 | 14.3% | -20.3% | ||
| Q4 24 | 8.9% | 26.8% | ||
| Q3 24 | 24.1% | -12.8% | ||
| Q2 24 | 34.6% | -8.3% | ||
| Q1 24 | 27.1% | 24.4% |
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 1.4% | ||
| Q4 24 | 6.7% | 2.1% | ||
| Q3 24 | 7.2% | 0.3% | ||
| Q2 24 | 3.3% | 0.2% | ||
| Q1 24 | 5.1% | 0.1% |
| Q4 25 | 1.35× | -0.03× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | -1.81× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SEAT
| Concerts | $34.3M | 35% |
| Resale | $29.3M | 30% |
| Theater | $24.4M | 25% |
| Private Label | $7.2M | 7% |
| Other | $2.2M | 2% |
